淀粉样肽前体蛋白抗体--性能参数，报价/价格，图片

基本信息

产品名称：

淀粉样肽前体蛋白抗体

英文名称：

Amyloid Precursor Protein

国产/进口：

国产

产地/品牌：

bioss

型号：

bs-0112M

参考报价：

销售商：

北京博奥森生物技术有限公司

总点击数：

586

更新日期：

2017-05-03

产品类别：

抗体

性能参数

产品编号	bs-0112M
英文名称	Amyloid Precursor Protein
中文名称	淀粉样肽前体蛋白抗体
别名	Secretory Amyloid Precursor Protein; Soluble APP-alpha; Soluble APP-beta; A4 amyloid protein; A4; AAA; ABETA; ABPP; AD 1; AD1; Alzheimer disease 1; Alzheimer disease; Alzheimer's disease amyloid protein; Amyloid beta (A4) precursor protein; Amyloid beta A4 protein; Amyloid beta A4 protein precursor isoform b; Amyloid beta A4 protein precursor isoform c; Amyloid beta A4 protein precursor isoform a; Amyloid beta A4 protein precursor isoform b; Amyloid beta A4 protein precursor isoform c; Amyloid beta protein; Amyloid beta-peptide; Amyloid of aging and alzheimer disease; APP; APP I; APPI; Beta am
规格价格	0.1ml/600元购买 0.2ml/1000元购买
说明书	0.1ml 0.2ml
研究领域	细胞生物神经生物学信号转导细胞凋亡 Alzheimer's
抗体来源	Mouse
克隆类型	Polyclonal
交叉反应	Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, Sheep,
产品应用	ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
分子量	72-83kDa
细胞定位	细胞核细胞浆细胞膜细胞外基质
性状	Lyophilized or Liquid
浓度	1mg/1ml
免疫原	KLH conjugated synthetic peptide derived from the middle of
亚型	IgG
纯化方法	affinity purified by Protein A
储存液	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
保存条件	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
生产商	BIOSS
PubMed	PubMed
产品介绍	background: This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]. Function: Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brai. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis. N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). Subunit: Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, NUMB and DAB. Binding to DAB1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains. Associates with microtubules in the presence of ATP and in a kinesin-dependent manner. Interacts, through a C-terminal domain, with GNAO1. Amyloid beta-42 binds CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 and AGER. Interacts with ANKS1B and TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts with IDE. Can form homodimers; this is promoted by heparin binding. Subcellular Location: Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment. Tissue Specificity: Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes. Post-translational modifications: Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region. Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin. Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). Beta-amyloid peptides are degraded by IDE. DISEASE: Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Defects in APP are the cause of amyloidosis cerebroarterial Dutch type (AMYLCAD) [MIM:605714]; also known as hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWAD). AMYLCAD is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. Beta-APP40 is the predominant form of cerebrovascular amyloid. Amyloid is not found outside the nervous system. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Onset of the disease is in middle age (44 to 60 years). Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease. Defects in APP are the cause of amyloidosis cerebroarterial Italian type (AMYLCAIT) [MIM:605714]. AMYLCAIT is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels, resulting in cerebral amyloid angiopathy. Amyloid is not found outside the nervous system. It is a condition very similar to AMYLCAD, but the clinical course is less severe. Patients manifest mild cognitive decline, recurrent strokes, and epilepsy in some cases. There are extensive amyloid deposits in leptomeningeal and cortical vessels and, to a lesser extent, in the neuropil of the cerebral cortex, in the absence of neurofibrillary tangles. Defects in APP are the cause of amyloidosis cerebroarterial Iowa type (AMYLCAIW) [MIM:605714]. AMYLCAIW is a hereditary amyloidosis due to amyloid-beta A4 peptide(s) deposition. Patients have progressive aphasic dementia, leukoencephalopathy, and occipital calcifications. Similarity: Belongs to the APP family. Contains 1 BPTI/Kunitz inhibitor domain. Gene ID: 351 Database links: Entrez Gene: 351 Human Entrez Gene: 11820 Mouse Entrez Gene: 54226 Rat Omim: 104760 Human SwissProt: P05067 Human SwissProt: P12023 Mouse SwissProt: P08592 Rat Unigene: 434980 Human Unigene: 277585 Mouse Unigene: 489029 Mouse Unigene: 490986 Mouse Unigene: 2104 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. APP695 （Amyloid protein precursor）淀粉样蛋白前体蛋白是一种大的细胞膜蛋白，其N端伸出于细胞外。该蛋白遭到破坏并释放出42个氨基酸的β-淀粉样肽，在老年斑和血管中被发现。这些异常蛋白可能积聚，而导致细胞失调和神经元的损伤。在研究APP与AD的关系中，该抗体十分重要。

公司简介

北京博奥森生物技术有限公司成立于2001年，注册资本2000万元，是集免疫学科研试剂研发、生产、销售为一体的国家高新技术企业。在公司近1300平米的研发中心楼内，拥有SPF级实验动物房、GMP级单克隆抗体制备平台，同时购置了CSBio多肽合成仪、Akta全自动液相色谱系统、BD流式细胞仪、Leica冷冻切片机等多种生产、检测仪器。公司还拥有一批技术精湛、经验丰富的科研开发团队，在免疫和分子生物学等领域拥有多项自主知识产权。

自成立之初，公司始终秉持“自主研发、原始创新，为全球生命科学研究提供优质服务”的经营理念。提供全面的科研抗体、试剂，诊断抗体原料，以及CRO服务。公司现拥有近两万种抗体产品，涵盖人蛋白靶点13000多个。特色产品有特异磷酸化抗体及专利授权AF荧光标记抗体等。此外，公司还提供完善的单/多克隆抗体制备、标记、重组蛋白、多肽合成及各项免疫学检测技术服务等。公司恪守ISO9001:2008国际质量管理体系认证要求，致力于打造“Bioss”精品抗体品牌。 2010年博奥森（波士顿）在美国设立了面向全球抗体市场的商务拓展及国际市场营销总部，不断扩展全球销售体系，主打Bioss国际品牌，向全球科研工作者提供高质量的科研抗体产品。迄今为止，Bioss产品已遍布全球多个国家和地区，并已成为数家国际知名抗体公司的OEM合作伙伴。Bioss抗体产品已出现在数千篇高质量SCI文章中，获得了全世界众多生命科学领域科研人员的认可。

百舸争流，只争朝夕。近二十年的探索和拼搏，为Bioss品牌在免疫学试剂领域奠定了坚实的基础。我们将在未来勇于开拓，自主创新，为生命科学研究提供更加优质的产品和服务，回报全球用户的信任，为生命科学进步尽绵薄之力。

温馨提示：产品仅用于实验室科研及非临床用途。

售后服务

1、所有书面反馈,我们收到后48小时内给出答复； 2、自2016年7月20日起，我公司所出售产品，质保期由原来的3-6个月，调整为1年，即产品发货之日起开始计算，1年内出现质量问题填写反馈表发送至sales@bioss.com.cn邮箱，博奥森公司给予退换货处理；超过1年的产品质量投诉只提供技术支持不提供退换货服务。